BioNTech BNTX shares are trading higher amid continued vaccine hopes, with President Trump's recent COVID-19 diagnosis adding to pandemic concerns and bringing further attention to vaccine and treatment names.
Trump, along with other notable political figures such as Kellyanne Conway and Chris Christie, brought renewed volatility to Covid-19 treatment and vaccine names after many politicians tested positive for the virus within the past week.
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19.
BioNTech was trading 7.87% higher at $79.50 at time of publication. The stock has a 52-week high of $105 and a 52-week low of $12.52.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
